Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models

Isr J Med Sci. Sep-Oct 1988;24(9-10):512-7.

Abstract

In this report we review our preclinical studies on the antitumor efficacy of L-DXR, using negatively charged sonicated vesicles. Animal studies indicate that various L-DXR formulations are more active than F-DXR on tumors infiltrating the liver and spleen, organs where liposomes are accumulated, and are equally effective on bone marrow-residing leukemic cells. In contrast, F-DXR was more effective than L-DXR when i.v.-administered, mg-equivalent doses were tested against ascitic and subcutaneously implanted tumors. Intraperitoneal administration of L-DXR was significantly more effective and approximately twofold less toxic than F-DXR in the treatment of an ascitic tumor. The antitumor effect correlated well with differences in drug levels in the relevant anatomic areas. These observations stress the site-specific activity of L-DXR and its dependence on biodistribution factor.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Ascites
  • Bone Marrow
  • Bone Neoplasms / drug therapy
  • Doxorubicin / administration & dosage*
  • Drug Carriers
  • Leukemia, Experimental / drug therapy
  • Liposomes
  • Liver Neoplasms / drug therapy
  • Lymphoma / drug therapy
  • Mice
  • Mice, Inbred BALB C
  • Neoplasms, Experimental / drug therapy*
  • Splenic Neoplasms / drug therapy

Substances

  • Drug Carriers
  • Liposomes
  • Doxorubicin